Literature DB >> 6606015

Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I.

M Howard, L Matis, T R Malek, E Shevach, W Kell, D Cohen, K Nakanishi, W E Paul.   

Abstract

Antigen-activated T lymphocytes produce within 24 h of stimulation a factor that is indistinguishable biochemically and functionally from the B cell co-stimulating growth factor, BCGF-I, originally identified in induced EL4 supernatants: Supernatants from antigen-stimulated T cell lines are not directly mitogenic for resting B cells, but synergize in an H-2-unrestricted manner with anti-Ig activated B cells to produce polyclonal proliferation but not antibody-forming-cell development; biochemical studies reveal the B cell co-stimulating factor present in antigen-stimulated T cell line supernatants is identical by phenyl Sepharose chromatography and isoelectric focusing (IEF) to EL4 supernatant BCGF-I. We thus conclude that normal T cells produce BCGF-I in response to antigenic stimulation. Analysis of the mechanism of BCGF-I production by antigen-stimulated T cells showed that optimum amounts of BCGF-I were obtained as quickly as 24 h post-stimulation, and that the factor producing cells in the T cell line investigated bore the Lyt-1+2- phenotype. As few as 10(4) T cells produced sufficient BCGF-I to support the proliferation of 5 X 10(4) purified anti-Ig activated B cells. Finally, the activation of normal T cell lines to produce BCGF-I required either antigen presented in the context of syngeneic antigen-presenting cells (APC) or interleukin 2 (IL-2).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6606015      PMCID: PMC2187160          DOI: 10.1084/jem.158.6.2024

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  37 in total

Review 1.  A third signal in B cell activation given by TRF.

Authors:  A Schimpl; E Wecker
Journal:  Transplant Rev       Date:  1975

2.  B lymphocyte activation by insoluble anti-immunoglobulin: induction of immunoglobulin secretion by a T cell-dependent soluble factor.

Authors:  D C Parker; J J Fothergill; D C Wadsworth
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

3.  The growth of mouse bone marrow cells in vitro.

Authors:  T R Bradley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1966-06

4.  H-2-unrestricted polyclonal maturation without replication of small B cells induced by antigen-activated T cell help factors.

Authors:  F Melchers; J Andersson; W Lernhardt; M H Schreier
Journal:  Eur J Immunol       Date:  1980-09       Impact factor: 5.532

5.  Stimulation of macrophage plasminogen activator activity by colony-stimulating factors.

Authors:  J A Hamilton; E R Stanley; A W Burgess; R K Shadduck
Journal:  J Cell Physiol       Date:  1980-06       Impact factor: 6.384

Review 6.  Regulation of B-cell growth and differentiation by soluble factors.

Authors:  M Howard; W E Paul
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

7.  Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages.

Authors:  E Handman; A W Burgess
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

8.  Activation of mouse lymphocytes by anti-immunoglobulin. I. Parameters of the proliferative response.

Authors:  D G Sieckmann; R Asofsky; D E Mosier; I M Zitron; W E Paul
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

9.  Biochemical and biological characterization of lymphocyte regulatory molecules. I. Purification of a class of murine lymphokines.

Authors:  J Watson; S Gillis; J Marbrook; D Mochizuki; K A Smith
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

10.  Antigen-reactive T cell clones. I. Transcomplementing hybrid I-A-region gene products function effectively in antigen presentation.

Authors:  M Kimoto; C G Fathman
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Lymphocyte proliferation, lymphokine production, and lymphocyte receptors in ageing and various clinical conditions.

Authors:  A L de Weck; F Kristensen; F Joncourt; F Bettens; C Walker; Y Wang
Journal:  Springer Semin Immunopathol       Date:  1984

2.  In vitro effects of gold sodium thiomalate on IL-1, IL-2 production, IL-2 receptor expression and IL-2 responsiveness in thymocytes and peripheral blood mononuclear cells.

Authors:  E Blitstein-Willinger; A Streller
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

3.  IL-2 infusion abrogates humoral immune responses in humans.

Authors:  D J Gottlieb; H G Prentice; H E Heslop; C Bello; M K Brenner
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

4.  Both interleukin 2 and a second T cell-derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis.

Authors:  K Nakanishi; T R Malek; K A Smith; T Hamaoka; E M Shevach; W E Paul
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Interleukin 2-dependent release of interleukin 3 activity by T4+ human T-cell clones.

Authors:  A A Ythier; M Abbud-Filho; J M Williams; R Loertscher; M W Schuster; A Nowill; J A Hansen; D Maltezos; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

7.  Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen.

Authors:  R J Robb; W C Greene; C M Rusk
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

8.  Activated T lymphocytes in epiretinal membranes from eyes of patients with proliferative diabetic retinopathy.

Authors:  S Tang; K C Le-Ruppert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-01       Impact factor: 3.117

9.  Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.

Authors:  R Maekawa; M Matsumoto; T Kitagawa; M Harada; K Sato
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2).

Authors:  M Allegretta; M B Atkins; R A Dempsey; E C Bradley; M W Konrad; A Childs; S N Wolfe; J W Mier
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.